Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

British Medical Journal

Volumn 318, Issue 7202, 1999, Pages 87-90

  Löfdahl, Claes Göran ^a   Reiss, Theodore F ^b   Leff, Jonathan A ^b   Israel, Elliot ^c   Noonan, Michael J ^d   Finn, Albert F ^d   Seidenberg, Beth C ^b   Capizzi, Thomas ^b   Kundu, Sudeep ^b   Godard, Philippe ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; ACETIC ACID DERIVATIVE; GLUCOCORTICOID; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; EUROPE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; ADOLESCENT; AGED; CHRONIC DISEASE; DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; SINGLE BLIND PROCEDURE;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ASTHMA; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; LEUKOTRIENE ANTAGONISTS; LUNG; MALE; MIDDLE AGED; QUINOLINES; SINGLE-BLIND METHOD;

EID: 0033542645     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. US Department of Health and Human Services. National Heart, Lung, and Blood Institute/World Health Organisation Workshop Report. Global initiative for asthma: global strategy for asthma management and prevention. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, 1995. (Publication No 95-3659, chapter 7.)
2. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
3. Greening AP, Ind PW, Northfield M, Shaw G, on behalf of Allen and Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
4. Dworski RT, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-9.
5. Rididick CA, Ring WL, Baker JR, Hodulik CR, Bigby TD. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 1997;246:112-8.
6. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg BC, Edwards TB for the Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-20.
7. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurnery J, et al for the Montelukast Asthma Study Group. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998;11:1232-9.
8. Knorr B, Matz J, Bernstein JA, Nguyen H. Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children. a randomized, double-blind trial. JAMA 1998;279:1181-6.
9. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Treatment of mild asthma and exercise-induced bronchoconstriction with montelukast, a leukotriene receptor antagonist. N Engl J Med 1998;339:147-52.
10. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J (in press).
11. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic patients treated with and without inhaled corticosteroids. Thorax 1997;52:45-8.
12. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
13. Kundu S, Noonan N, Friedman BS, Reiss TF, Leff JA. Use of a composite clinical score allows safe tapering of inhaled corticosteroids in asthmatic patients. Am J Respir Crit Care Med 1997;155:A352.
14. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997;0:646-51.
15. American Thoracic Society. Standardization of spirometry. Am J Respir Crit Care Med 1995;152:1107-36.
16. Tamaoki J, Kondo M, Sakaj N, Nakata J, Takemura H, Nagai A, et al on behalf of the Tokyo Joshi-Idai Asthma Research Group. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled conticosteroid. Am J Respir Crit Care Med 1997;155:1235-40.
17. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157:S1-53.
18. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
19. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-208.
20. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996;153:1739-48.
21. Erzurum SE, Leff JA, Cochran JE, Ackerson LM, Szefler SJ, Martin RJ, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma. Ann Int Med 1991;114:353-60.